Gilead trumpets data with newly-bought magrolimab in blood cancers

cafead

Administrator
Staff member
  • cafead   Jun 01, 2020 at 12:12: AM
via Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.

article source
 

<